These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 30978462)

  • 1. Plasma metabolomics in early Alzheimer's disease patients diagnosed with amyloid biomarker.
    Peña-Bautista C; Roca M; Hervás D; Cuevas A; López-Cuevas R; Vento M; Baquero M; García-Blanco A; Cháfer-Pericás C
    J Proteomics; 2019 May; 200():144-152. PubMed ID: 30978462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Untargeted metabolomic analysis of human plasma indicates differentially affected polyamine and L-arginine metabolism in mild cognitive impairment subjects converting to Alzheimer's disease.
    Graham SF; Chevallier OP; Elliott CT; Hölscher C; Johnston J; McGuinness B; Kehoe PG; Passmore AP; Green BD
    PLoS One; 2015; 10(3):e0119452. PubMed ID: 25803028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of altered metabolic pathways in plasma and CSF in mild cognitive impairment and Alzheimer's disease using metabolomics.
    Trushina E; Dutta T; Persson XM; Mielke MM; Petersen RC
    PLoS One; 2013; 8(5):e63644. PubMed ID: 23700429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted Metabolomic Analysis of Soluble Lysates from Platelets of Patients with Mild Cognitive Impairment and Alzheimer's Disease Compared to Healthy Controls: Is PC aeC40:4 a Promising Diagnostic Tool?
    Oberacher H; Arnhard K; Linhart C; Diwo A; Marksteiner J; Humpel C
    J Alzheimers Dis; 2017; 57(2):493-504. PubMed ID: 28269764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-resolution metabolomic profiling of Alzheimer's disease in plasma.
    Niedzwiecki MM; Walker DI; Howell JC; Watts KD; Jones DP; Miller GW; Hu WT
    Ann Clin Transl Neurol; 2020 Jan; 7(1):36-45. PubMed ID: 31828981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Three plasma metabolites in elderly patients differentiate mild cognitive impairment and Alzheimer's disease: a pilot study.
    Costa AC; Joaquim HPG; Forlenza OV; Gattaz WF; Talib LL
    Eur Arch Psychiatry Clin Neurosci; 2020 Jun; 270(4):483-488. PubMed ID: 31218445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic profiling of Alzheimer's disease: Untargeted metabolomics analysis of plasma samples.
    Milos T; Rojo D; Nedic Erjavec G; Konjevod M; Tudor L; Vuic B; Svob Strac D; Uzun S; Mimica N; Kozumplik O; Barbas C; Zarkovic N; Pivac N; Nikolac Perkovic M
    Prog Neuropsychopharmacol Biol Psychiatry; 2023 Dec; 127():110830. PubMed ID: 37454721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Community-Based Study Identifying Metabolic Biomarkers of Mild Cognitive Impairment and Alzheimer's Disease Using Artificial Intelligence and Machine Learning.
    Yilmaz A; Ustun I; Ugur Z; Akyol S; Hu WT; Fiandaca MS; Mapstone M; Federoff H; Maddens M; Graham SF
    J Alzheimers Dis; 2020; 78(4):1381-1392. PubMed ID: 33164929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum metabolomic profiling in patients with Alzheimer disease and amnestic mild cognitive impairment by GC/MS.
    Sun C; Gao M; Wang F; Yun Y; Sun Q; Guo R; Yan C; Sun X; Li Y
    Biomed Chromatogr; 2020 Sep; 34(9):e4875. PubMed ID: 32384189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma amyloid levels within the Alzheimer's process and correlations with central biomarkers.
    Hanon O; Vidal JS; Lehmann S; Bombois S; Allinquant B; Tréluyer JM; Gelé P; Delmaire C; Blanc F; Mangin JF; Buée L; Touchon J; Hugon J; Vellas B; Galbrun E; Benetos A; Berrut G; Paillaud E; Wallon D; Castelnovo G; Volpe-Gillot L; Paccalin M; Robert PH; Godefroy O; Dantoine T; Camus V; Belmin J; Vandel P; Novella JL; Duron E; Rigaud AS; Schraen-Maschke S; Gabelle A;
    Alzheimers Dement; 2018 Jul; 14(7):858-868. PubMed ID: 29458036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma metabolic profiling of mild cognitive impairment and Alzheimer's disease using liquid chromatography/mass spectrometry.
    Liu Y; Li N; Zhou L; Li Q; Li W
    Cent Nerv Syst Agents Med Chem; 2014; 14(2):113-20. PubMed ID: 25515716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in Plasma Amyloid and Tau in a Longitudinal Study of Normal Aging, Mild Cognitive Impairment, and Alzheimer's Disease.
    Chen TB; Lai YH; Ke TL; Chen JP; Lee YJ; Lin SY; Lin PC; Wang PN; Cheng IH
    Dement Geriatr Cogn Disord; 2019; 48(3-4):180-195. PubMed ID: 31991443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of a Metabolic Signature Predisposing High Risk Patients with Mild Cognitive Impairment to Converting to Alzheimer's Disease.
    Huang YL; Lin CH; Tsai TH; Huang CH; Li JL; Chen LK; Li CH; Tsai TF; Wang PN
    Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identifying Hair Biomarker Candidates for Alzheimer's Disease Using Three High Resolution Mass Spectrometry-Based Untargeted Metabolomics Strategies.
    Chang CW; Hsu JY; Hsiao PZ; Chen YC; Liao PC
    J Am Soc Mass Spectrom; 2023 Apr; 34(4):550-561. PubMed ID: 36973238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolomic profiling of serum in the progression of Alzheimer's disease by capillary electrophoresis-mass spectrometry.
    González-Domínguez R; García A; García-Barrera T; Barbas C; Gómez-Ariza JL
    Electrophoresis; 2014 Dec; 35(23):3321-30. PubMed ID: 25136972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma metabolite profiles of Alzheimer's disease and mild cognitive impairment.
    Wang G; Zhou Y; Huang FJ; Tang HD; Xu XH; Liu JJ; Wang Y; Deng YL; Ren RJ; Xu W; Ma JF; Zhang YN; Zhao AH; Chen SD; Jia W
    J Proteome Res; 2014 May; 13(5):2649-58. PubMed ID: 24694177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-Throughput Metabolomics for Discovering Potential Metabolite Biomarkers and Metabolic Mechanism from the APPswe/PS1dE9 Transgenic Model of Alzheimer's Disease.
    Yu J; Kong L; Zhang A; Han Y; Liu Z; Sun H; Liu L; Wang X
    J Proteome Res; 2017 Sep; 16(9):3219-3228. PubMed ID: 28753016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolomic-Driven Elucidation of Serum Disturbances Associated with Alzheimer's Disease and Mild Cognitive Impairment.
    González-Domínguez R; Rupérez FJ; García-Barrera T; Barbas C; Gómez-Ariza JL
    Curr Alzheimer Res; 2016; 13(6):641-53. PubMed ID: 26825096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PiB-PET Imaging-Based Serum Proteome Profiles Predict Mild Cognitive Impairment and Alzheimer's Disease.
    Kang S; Jeong H; Baek JH; Lee SJ; Han SH; Cho HJ; Kim H; Hong HS; Kim YH; Yi EC; Seo SW; Na DL; Hwang D; Mook-Jung I
    J Alzheimers Dis; 2016 Jul; 53(4):1563-76. PubMed ID: 27392853
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.